Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.
Chemotherapy with TKI followed by TKI maintenance may leads to higher hypertension grade ≥ 3 compared with chemotherapy alone (low certainty).
The review found no eligible studies for this question.
Chemotherapy with TKI followed by TKI maintenance showed no clear difference in overall survival (OS) compared with chemotherapy alone (low certainty).
Chemotherapy with TKI followed by TKI maintenance probably leads to lower progression‐free survival (PFS) compared with chemotherapy alone (moderate certainty).
The review found no eligible studies for this question.
The review found no eligible studies for this question.
The review found no eligible studies for this question.
Chemotherapy with TKI followed by TKI maintenance showed no clear difference in overall survival (OS) compared with chemotherapy alone (moderate certainty).
Chemotherapy with TKI followed by TKI maintenance showed no clear difference in progression‐free survival (PSF) compared with chemotherapy alone (moderate certainty).
Low-level laser therapy (LLLT) + calcium hydroxide showed no clear difference in radiological failure compared with formocresol (FC); GRADE not reported.
Low-level laser therapy (LLLT) + calcium hydroxide showed no clear difference in radiological failure compared with calcium hydroxide (CH); GRADE not reported.
Low molecular weight heparin secondary prophylaxis showed no clear difference in all‐cause mortality (main analysis ‐ active cancer) compared with vitamin K antagonist secondary prophylaxis (low certainty).
Low molecular weight heparin secondary prophylaxis showed no clear difference in all‐cause mortality (time‐to‐event) compared with vitamin K antagonist secondary prophylaxis (low certainty).
Low molecular weight heparin secondary prophylaxis probably leads to lower recurrent venous thromboembolism (main analysis ‐ active cancer) compared with vitamin K antagonist secondary prophylaxis (moderate certainty).
Low molecular weight heparin secondary prophylaxis probably leads to lower recurrent venous thromboembolism (time‐to‐event) compared with vitamin K antagonist secondary prophylaxis (moderate certainty).
Low molecular weight heparin secondary prophylaxis showed no clear difference in major bleeding (main analysis ‐ active cancer) compared with vitamin K antagonist secondary prophylaxis (low certainty).
It is very uncertain whether low molecular weight heparin secondary prophylaxis changes minor bleeding (main analysis ‐ active cancer) compared with vitamin K antagonist secondary prophylaxis (very low certainty).